Clinical trials
BRCA Mutation clinical trials
Below are recruiting brca mutation clinical trials, each written for real people, not researchers. We’re tracking 27 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06177171RecruitingPhase 1
Olaparib and ASTX727 for DNA repair-deficient cancers
This trial tests a combination of two drugs—olaparib (a PARP inhibitor) and ASTX727 (a DNA hypomethylating agent)—for people whose cancers have a specific DNA repair flaw. The goal is to see if this combination can shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT05485766RecruitingPhase 2
Pembrolizumab with cancer medicines for BRCA-mutated triple negative breast cancer
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
Gifu, GifuAges 18 years+ - NCT06831747Recruiting
Mini-incision vs standard laparoscopy for preventive ovary removal in BRCA
This trial compares two ways to do preventive ovary-removal surgery: one using a single tiny incision and the other using a standard laparoscopic approach. The goal is to see which method works better for women with a BRCA gene mutation.
Udine, UdineAges 18 years+ - NCT06405295Enrolling by invitation
Intensive adjuvant therapy for BRCA-related triple-negative breast cancer
This trial tests an intensive add-on treatment for people with triple-negative breast cancer and a BRCA mutation who are at high risk of recurrence after surgery and standard treatments. The goal is to see if extra therapy helps prevent the cancer from coming back.
Beijing, Beijing MunicipalityAges 18–75 - NCT07292246Recruiting
HandX-assisted endoscopic mastectomy study for breast cancer
This trial tests a new, less invasive way to remove breast tissue using a small camera (endoscope) with a device called HandX. It's for women who need a mastectomy for early-stage breast cancer, DCIS, or to reduce high risk, and aims to see if it's safe and works well.
Glyfada, AtticaAges 18 years+ - NCT05097274Recruiting
PET-CT scan for men with prostate cancer and a DNA repair mutation
This study uses a special scan (FCH-PET-CT) to help doctors see prostate cancer more clearly in men who have a known gene change involved in DNA repair. It’s meant to improve staging and assessment, especially around when imaging is needed.
London, Sutton, SurreyAges 18 years+ - NCT06792721Recruiting
Measuring mutation levels in siblings with BRCA risk
This study looks at how genetic mutations (changes in DNA) are measured in the blood of sisters. One sister has a BRCA1 or BRCA2 gene mutation that raises cancer risk, and the other does not. The goal is to understand mutation differences between them.
Caen, FranceAges 30–50 - NCT06395519RecruitingPhase 1/Phase 2
Study of ETX-19477 for advanced solid tumors
This trial tests an experimental drug called ETX-19477 for people with advanced solid tumors that have stopped responding to other treatments. It aims to see if the drug is safe and effective, especially for those with certain genetic changes (BRCA2 mutations).
Phoenix, ArizonaAges 18 years+ - NCT05576389RecruitingPhase 2
Fluzoparib plus camrelizumab before surgery for BRCA-related HER2-negative breast cancer
This study tests a combination of two drugs – fluzoparib (a PARP inhibitor) and camrelizumab (an immunotherapy) – given before surgery for early-stage or locally advanced HER2-negative breast cancer in people with an inherited BRCA mutation. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05769517Recruiting
Using ultrasound to predict BRCA genes from healthy ovaries
This study looks at whether pictures from a vaginal (transvaginal) ultrasound of a healthy ovary can help predict whether someone carries BRCA1 or BRCA2 gene changes. It may help identify people who could benefit from more genetic testing, without needing new ultrasound images.
RomeAges Any age - NCT07253051Recruiting
Study for women with BRCA gene mutations
This study creates a platform for women who carry a BRCA1 or BRCA2 gene mutation to be followed over time. It aims to better understand and manage cancer risks associated with these mutations.
AvellinoAges 18 years+ - NCT06588322Recruiting
Detecting gene changes in blood of ovarian cancer patients on PARP inhibitor
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
AngersAges 18 years+ - NCT03544983Enrolling by invitation
Genetic education program for BRCA family members
This trial offers education about BRCA1 and BRCA2 gene mutations to help families understand testing, cancer risk, and next steps. It may be helpful if you are a family member of someone who recently learned they have a BRCA mutation.
Washington D.C., District of ColumbiaAges 21–75 - NCT06516289RecruitingPhase 2
Neoadjuvant treatment for BRCA-mutated HER2-negative breast cancer
This trial tests a combination of two oral medications (HRS-1167 and famitinib) with or without an immunotherapy drug (camrelizumab) before surgery for women with a BRCA gene mutation and HER2-negative breast cancer. It aims to see if these drugs can shrink tumors before surgery.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT04090567RecruitingPhase 2
Olaparib with two partners for advanced BRCA breast cancer
This trial tests whether the drug olaparib works better when combined with cediranib or AZD6738 in people with advanced or metastatic BRCA (inherited) breast cancer. It may help shrink tumors or slow cancer growth after prior treatment with a PARP inhibitor.
Houston, TexasAges 18 years+ - NCT06952803RecruitingPhase 3
Testing a new drug for men with BRCA-related prostate cancer
This trial tests whether adding a new drug (saruparib) to standard radiation and hormone therapy can help prevent prostate cancer from spreading to other parts of the body. It is for men with high-risk prostate cancer that has a BRCA gene mutation.
Phoenix, ArizonaAges 18 years+ - NCT05420779RecruitingPhase 2
TSL-1502 for breast cancer with BRCA gene mutations
This Phase 2 trial tests TSL-1502 capsules, a targeted medicine for breast cancer, in people whose blood test shows a harmful BRCA gene mutation. It aims to see whether it can control the cancer and how safe it is after prior treatment.
BeijingAges 18–75 - NCT06666270RecruitingPhase 1
SYN818 for advanced solid tumors with DNA repair defects
This trial tests a new drug called SYN818 for people with advanced breast, ovarian, prostate, or other solid tumors that have stopped responding to standard treatments. It is designed for patients whose tumors have a specific DNA repair problem (BRCA mutation or other HR pathway deficiency).
Zhengzhou, HenanAges 18 years+ - NCT06783127Recruiting
Olaparib for BRCA-related prostate cancer
This trial studies how well olaparib works for men with metastatic castration-resistant prostate cancer that has a BRCA mutation. It looks at results from real-world use, not a controlled study.
NaplesAges Any age - NCT07039552Recruiting
Ovarian cancer risk check for family members
This study looks at family members of people with ovarian cancer to build a better tool for predicting their risk. If you have a BRCA1 or BRCA2 gene mutation, you may be able to join.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07069335RecruitingPhase 1
Studying a new form of olaparib for BRCA-mutated ovarian cancer
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
Seoul, Songpa DistrictAges 19–74 - NCT07371104RecruitingPhase 1
Study of DWZ2501 in advanced BRCA ovarian cancer on olaparib
This trial compares how the body processes a new formulation of olaparib (DWZ2501) versus the standard version. It is for women with advanced, BRCA-mutated high-grade ovarian cancer who are already on or about to start a stable dose of olaparib 300 mg twice daily.
Seoul, Jongno-guAges 19 years+ - NCT00823654Recruiting
Blood tests during treatment to track ovarian egg supply
This study measures blood biomarkers to understand how breast cancer treatment affects a person’s future fertility (ovarian reserve). It may help patients learn more about egg supply changes after chemotherapy and hormone-related treatments.
Basking Ridge, New JerseyAges 18–44 - NCT06470685Enrolling by invitation
Preventive prostate removal for prostate cancer risk
This study tests whether removing the prostate before cancer develops can help people at higher risk, such as those with certain gene changes (like BRCA2), a strong family history, or Black African/Caribbean ancestry. It also includes people who have already had their prostate removed for cancer treatment.
LondonAges 18 years+
Hear when a new BRCA Mutation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for brca mutation?
- Yes. Clin2 currently lists 27 recruiting brca mutation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a brca mutation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a brca mutation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.